Benigne und maligne Bindehauttumoren in Diagnostik und Therapie
- 10 August 2020
- journal article
- research article
- Published by Georg Thieme Verlag KG in Augenheilkunde up2date
- Vol. 10 (03) , 223-239
Abstract
Bindehauttumoren betreffen in Diagnostik und Therapie alle Bereiche der augenärztlichen Praxis. Das beginnt mit der klinischen Kontrolle von Bindehautnävi und anderen benignen Tumoren, der Einschätzung von entzündlichen Pseudotumoren und ihrer Abgrenzung zu Präkanzerosen oder vernarbenden Erkrankungen und mündet in der hochspezialisierten und interdisziplinären Führung onkologischer Patienten mit Lymphomen, hochmalignen Melanomen oder invasiven Plattenepithelkarzinomen. The aim of this paper is to give an overview of different benign and malignant epibulbar tumors. Categories can be made of the age of manifestation (paediatric tumors versus tumors of adults), the originating cell types (squamous cell tumors, melanocytic tumors, lymphomas or germ cell tumors) or genesis (proliferative, infectious or degenerating tumors). Most epibulbar tumors show lesions on the conjunctiva or the cornea. These can be flesh coloured or pigmented efflorescences with leucoplakias or hyperkeratosis. Especially malignant tumors show atypical growth of blood vessels, are often prominent and can have ulcerations or bleeding. In case of tumor growth, change in pigmentations or atypical bleedings a malign tumor can be suspected. The diagnosis should be confirmed using histopathological evaluation after an incisional or excisional biopsy. Molecular pathologic techniques extend the diagnostic tools and have an implication on the therapy of metastatic tumors. Therapeutic options of the malignant tumors (apart from lymphomas) are chirurgical excision preferably with a no touch technique and afterwards an adjuvant therapy consisting of radiation or cryotherapy. A topical chemotherapy with Mitomycin C, 5-Fluorouracil or Interferon α2b can be effective to reduce persisting precancerosis and reduce recurrences. In case of a suspected malignant tumor it is advisable to refer the patient to an ophthalmo-oncologic center to plan and ensure interdisciplinary therapy. Publication Date: 10 August 2020 (online) Georg Thieme Verlag KG Stuttgart · New YorkKeywords
This publication has 47 references indexed in Scilit:
- Management of pediatric corneal limbal dermoidsClinical Ophthalmology, 2013
- Association of human papilloma virus with pterygia and ocular-surface squamous neoplasiaEye, 2011
- Squamous Cell Carcinoma of the Eyelid and ConjunctivaInternational Ophthalmology Clinics, 2009
- Ocular Adnexal Lymphoid Tumors: Progress in Need of ClarificationAmerican Journal of Ophthalmology, 2008
- An audit of conjunctival melanoma treatment in LiverpoolEye, 2008
- "Finger-tip" cryotherapy probes: treatment of squamous and melanocytic conjunctival neoplasiaBritish Journal of Ophthalmology, 2005
- Anti‐CD20 monoclonal antibody therapy in relapsed MALT lymphoma of the conjunctivaEuropean Journal of Haematology, 2004
- Clinical survey of 1643 melanocytic and nonmelanocytic conjunctival tumorsOphthalmology, 2004
- Survey of 1264 patients with orbital tumors and simulating lesionsOphthalmology, 2004
- Conjunctival malignant melanoma in Sweden 1969‐91Acta Ophthalmologica, 1992